Alaunos doubles TCR library addressable market; cash runway into Q4 2023

Alaunos Therapeutics, Inc.

Added two new TCRs to library, doubling addressable market; targets KRAS, TP53, EGFR hotspot mutations.
Enrolling patients in TCR-T Phase 1/2; third patient dosed Dec 2022; interim data expected mid-2023.
Manufacturing capacity doubled; moving to cryopreserved product reduces process time 13% (30 to 26 days).
mbIL-15 program IND filing anticipated H2 2023.
Cash $39.1M (unaudited) plus $13.9M restricted; runway into Q4 2023; operating cash flow $35-40M in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.